Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators. Meneghini L, et al. Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22. Diabetes Care. 2013. PMID: 23340894 Free PMC article. Clinical Trial.
Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.
Pettus J, Roussel R, Liz Zhou F, Bosnyak Z, Westerbacka J, Berria R, Jimenez J, Eliasson B, Hramiak I, Bailey T, Meneghini L. Pettus J, et al. Among authors: meneghini l. Diabetes Ther. 2019 Apr;10(2):617-633. doi: 10.1007/s13300-019-0568-8. Epub 2019 Feb 14. Diabetes Ther. 2019. PMID: 30767173 Free PMC article.
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
Meneghini LF, Mauricio D, Orsi E, Lalic NM, Cali AMG, Westerbacka J, Stella P, Candelas Dea C, Pilorget V, Perfetti R, Khunti K; DUNE investigators. Meneghini LF, et al. Diabetes Obes Metab. 2019 Jun;21(6):1429-1436. doi: 10.1111/dom.13673. Epub 2019 Mar 28. Diabetes Obes Metab. 2019. PMID: 30768845 Free PMC article.
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Meneghini L, Blonde L, Gill J, Dauchy A, Bacevicius A, Strong J, Bailey TS. Meneghini L, et al. Diabetes Obes Metab. 2020 Nov;22(11):1995-2003. doi: 10.1111/dom.14116. Epub 2020 Jul 27. Diabetes Obes Metab. 2020. PMID: 32538550 Free PMC article. Clinical Trial.
More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
Frias J, Puig Domingo M, Meneghini L, Napoli R, Liu M, Soltes Rak E, Aroda VR. Frias J, et al. Among authors: meneghini l. Diabetes Obes Metab. 2018 Sep;20(9):2314-2318. doi: 10.1111/dom.13368. Epub 2018 Jun 13. Diabetes Obes Metab. 2018. PMID: 29785837 Free PMC article.
145 results